JP2009515953A - 軟骨障害に関連した使用のための薬物 - Google Patents

軟骨障害に関連した使用のための薬物 Download PDF

Info

Publication number
JP2009515953A
JP2009515953A JP2008541124A JP2008541124A JP2009515953A JP 2009515953 A JP2009515953 A JP 2009515953A JP 2008541124 A JP2008541124 A JP 2008541124A JP 2008541124 A JP2008541124 A JP 2008541124A JP 2009515953 A JP2009515953 A JP 2009515953A
Authority
JP
Japan
Prior art keywords
akg
use according
amino acid
rats
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008541124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009515953A5 (enExample
Inventor
ステファン ピエルジノヴスキ，
Original Assignee
エントレス アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エントレス アーベー filed Critical エントレス アーベー
Publication of JP2009515953A publication Critical patent/JP2009515953A/ja
Publication of JP2009515953A5 publication Critical patent/JP2009515953A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008541124A 2005-11-15 2006-11-15 軟骨障害に関連した使用のための薬物 Pending JP2009515953A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59717205P 2005-11-15 2005-11-15
PCT/SE2006/050479 WO2007058612A1 (en) 2005-11-15 2006-11-15 Medicament for use in connection with cartilage impairment

Publications (2)

Publication Number Publication Date
JP2009515953A true JP2009515953A (ja) 2009-04-16
JP2009515953A5 JP2009515953A5 (enExample) 2010-07-08

Family

ID=38048916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541124A Pending JP2009515953A (ja) 2005-11-15 2006-11-15 軟骨障害に関連した使用のための薬物

Country Status (10)

Country Link
US (2) US20090312427A1 (enExample)
EP (1) EP1951218A4 (enExample)
JP (1) JP2009515953A (enExample)
KR (1) KR20080074182A (enExample)
CN (2) CN101843609A (enExample)
AU (1) AU2006316059A1 (enExample)
BR (1) BRPI0618599A2 (enExample)
CA (1) CA2629683A1 (enExample)
RU (1) RU2454999C2 (enExample)
WO (1) WO2007058612A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090312427A1 (en) * 2005-11-15 2009-12-17 Entress Ab Medicament for Use in Connection With Cartilage Impairment
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
EP2106791A1 (en) * 2008-03-31 2009-10-07 Biotempt B.V. Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation
KR101080271B1 (ko) * 2009-03-31 2011-11-08 주식회사 웰스킨 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제용 화장품 조성물
WO2011126163A1 (ko) * 2010-04-08 2011-10-13 주식회사 웰스킨 다이펩타이드를 포함하는 피부 미백용 조성물
CN113018288A (zh) * 2019-12-25 2021-06-25 同济大学 α-酮戊二酸在制备药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098619A2 (en) * 2003-05-07 2004-11-18 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
WO2005077356A2 (en) * 2004-02-09 2005-08-25 Hill's Pet Nutrition, Inc. Glycine and/or for use in cartilage affecting conditions
JP2005312402A (ja) * 2004-04-30 2005-11-10 Kanazawa Univ Tlo Inc グルタミン酸伝達系を利用した骨・軟骨疾患治療薬の評価方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
WO1998059035A2 (en) * 1997-06-25 1998-12-30 The Goverment Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services, National Institutes Of Health Serum-free cell growth medium
US6846501B2 (en) * 2000-04-12 2005-01-25 Mid-America Commercialization Corporation Traditional snacks having balanced nutritional profiles
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
RU2211037C1 (ru) * 2001-12-29 2003-08-27 Институт органической и физической химии им. А.Е.Арбузова Казанского научного центра РАН Препарат селективного действия и способ лечения остеоартрозов
WO2004028448A2 (en) * 2002-09-13 2004-04-08 Miller Kenneth E Method of alleviating pain via inhibition of neurotransmitter synthesis
PL368573A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound influencing growth and mineralization processes in the axial and the appendicular skeleton as well as bone diseases of mature years among humans and animals as well as application of the pharmaceutical compound in the process of growth and mineralization of axial and appendicular skeleton and bone diseases of mature years among humans and animals
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20090312427A1 (en) * 2005-11-15 2009-12-17 Entress Ab Medicament for Use in Connection With Cartilage Impairment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004098619A2 (en) * 2003-05-07 2004-11-18 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
WO2005077356A2 (en) * 2004-02-09 2005-08-25 Hill's Pet Nutrition, Inc. Glycine and/or for use in cartilage affecting conditions
JP2005312402A (ja) * 2004-04-30 2005-11-10 Kanazawa Univ Tlo Inc グルタミン酸伝達系を利用した骨・軟骨疾患治療薬の評価方法

Also Published As

Publication number Publication date
CN101309678A (zh) 2008-11-19
KR20080074182A (ko) 2008-08-12
CN101309678B (zh) 2011-04-20
WO2007058612A1 (en) 2007-05-24
CN101843609A (zh) 2010-09-29
US20090312427A1 (en) 2009-12-17
RU2008123806A (ru) 2009-12-27
HK1126128A1 (en) 2009-08-28
AU2006316059A1 (en) 2007-05-24
RU2454999C2 (ru) 2012-07-10
US20110082086A1 (en) 2011-04-07
BRPI0618599A2 (pt) 2011-09-06
CA2629683A1 (en) 2007-05-24
EP1951218A4 (en) 2010-11-10
EP1951218A1 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
KR100679778B1 (ko) PTHrP 유사체를 사용하는 골절 치료법
JPH0772138B2 (ja) 骨質量増加用医薬複合剤
US20110082086A1 (en) Medicament for use in connection with cartilage impairment
JP4447913B2 (ja) オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用
EP0460080B1 (en) Orally administerable calcium supplement for cattle
JP2024074977A (ja) Ｌｌｐ２ａ－ビスホスホネート化合物を用いて骨壊死を処置する方法
JP6218732B2 (ja) 変形性関節症予防又は治療用組成物
KR20070040371A (ko) 혈장 지질을 낮추기 위한 알파 케토글루타레이트 및 관련화합물의 용도
US20070161551A1 (en) Methods and compositions for the treatment of lipodystrophy
JP4652689B2 (ja) 骨再生を促進するカルモジュリンの使用
MX2008006203A (en) Medicament for use in connection with cartilage impairment
HK1145285A (en) Medicament for use in connection with cartilage impairment
HK1126128B (en) Medicament for use in connection with cartilage impairment
JP2006256985A (ja) 貝殻から得られるカルシウム塩結晶化抑制蛋白とその製造方法、ならびにその利用
EP4003388A1 (en) Composition for and method of improving tissue performance
JP2007519669A (ja) 脂肪異栄養症を治療するための方法及び組成物
JP2004010533A (ja) 軟骨生成促進剤及び軟骨損傷由来疾病予防治療剤
JPWO2018003817A1 (ja) 骨形成不全症等の予防及び／又は治療剤
JP2023048160A (ja) 破骨細胞分化抑制、筋肉量増加、運動機能改善、及び／又は筋力増強用組成物
JP2024539038A (ja) 軟骨保護栄養補助食品組成物及びその使用方法
JP2023144116A (ja) 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤
JP4998880B2 (ja) 骨粗鬆症の予防又は改善剤
JPWO2017006908A1 (ja) 特発性大腿骨頭壊死症の発症予防及び／又は進行抑制剤
HK1242607A1 (en) Agent for preventing onset of idiopathic osteonecrosis of femoral head and/or suppressing progress of same
MXPA06007761A (en) Methods and compositions for the treatment of lipodystrophy

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20080711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121030